[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@3primeAnalytica Avatar @3primeAnalytica 3PrimeAnalytica

3PrimeAnalytica posts on X about $regn, $beam, collab, vivo the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence

Social category influence stocks cryptocurrencies technology brands finance

Social topic influence $regn #36, $beam #35, collab, vivo, investment, $crsp, $ntla, $sana, $crbu, gain

Top accounts mentioned or mentioned by @geneinvesting @biotech2k1 @regeneron @beamtx @crisprtx @yaireinhorn @tohjah7809 @razorsharpdna @intelliatx @primemedicine @oliverventure @xdilaudeadx @nataninvesting @byte8alchemist @rnaianalyst @bradloncar @jessiechimni @bowtiedbiotech @cathiedwood @zhaoweiasu

Top assets mentioned Regeneron Pharmaceuticals Inc (REGN) BEAM (BEAM) CRISPR Therapeutics AG (CRSP) Intellia Therapeutics, Inc (NTLA)

Top Social Posts

Top posts by engagements in the last XX hours

"🚨 Regulatory Tailwinds for Gene Editing Companies Regulatory advancements are emerging globally potentially benefiting the gene-editing sector by streamlining approval processes reducing evidentiary requirements and introducing expedited pathways. Companies such as $CRSP $NTLA $BEAM $SANA and $CRBU stand to gain significantly. This post outlines key developments. If you know of others please share in the replies. FDA's Conditional Approval Pathway for Rare Diseases Announced in April 2025 - This mechanism enables conditional approvals based on plausible biological mechanisms for ultra-rare"
X Link 2025-08-25T18:18Z 1381 followers, 3875 engagements

"🚨 $REGN and Tessera Therapeutics have announced collab to develop TSRA-196 Tesseras lead in vivo Gene Writing candidate for AATD. Deal terms: -$150 M upfront (cash + equity investment) -Up to $XXX M in near- and mid-term R&D milestones -50/50 global cost- and profit-sharing -IND filing expected by end of 2025"
X Link 2025-12-01T15:46Z 1382 followers, 5909 engagements

"This marks $REGN's 5th major platform-level commitment to next-gen genetic medicines in just X years - a deliberate disciplined strategy that has now seen the company deploy $1.3bn in upfront cash and equity across the most promising technologies in the space. This is a systematic build-out of a complete genetic medicines toolkit backed by the worlds best human genetics engine.the RGC (Regeneron Genetics Center). ✅2016 $NTLA $125m (CRISPR) ✅2019 $ALNY $800m (RNAi) ✅2023 Decibel $109m (AAV GT) ✅2024 Mammoth $XX (CRISPR) ✅2025 Tessera $150m (GW) 👆If you think George and Len just dropped $150m"
X Link 2025-12-01T16:53Z 1381 followers, 4648 engagements

"$REGN Fireside Chat at Evercore ISI Key Takeaways ☕ Marion (CCO) + Crowe (EVP R&D) as usual delivered a very confident detailed and fwd-looking discussion today. Clear pride in a highly productive 2025 across com. execution pipe dev. and capital allocation & with firm conviction for 2026. Tone was the usual consistently upbeat zero defensiveness - pure Regeneron execution mode. 📍 2025 highlights from Marion - EYLEA HD continued strong share gains + newly launched Q4w dosing & RVO indication (RVO 1718% of legacy EYLEA business XX% of total anti-VEGF market) - Dupi now X indications in US"
X Link 2025-12-03T00:07Z 1381 followers, 1098 engagements

"again calculated risk spreading from REGN and with a good target something you need to learn.they see little risk from (likely not of) prme bring it to court prme has many other fish to TRY and fry/existential priorities for now.this is typical REGN allocating capital across uncorrelated return streams within a specific segment of the market. not sure why im arguing about risk with you"
X Link 2025-12-01T20:49Z 1380 followers, XXX engagements

"🚨 $BEAM BEACON update looksoutstanding. -With XX pts treated (data cutoff Aug. X 2025) and follow-up extending to 20.4m the dataset's maturity has advanced meaningfully. -Core bio and clinical signals remain not just consistent but solid vs. prior readoutsno attenuation of fetal haemoglobin (HbF) no new safety concerns and XXX% severe VOC-free post-engraftment. ✅editing rates XXXX% at month XXXXX% at month XX ✅Mean HbF sustained XX% with highly pancell distribution (95% F-cells typically carrying protective levels) ✅HbS durably XX% (mean 3035%). ✅Total Hb rapid rise to normal ranges;"
X Link 2025-12-06T17:01Z 1380 followers, 2213 engagements